Clinical trial registry record

Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 17, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04314011
Last registry update
March 17, 2022
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
Shanghai East Hospital
Enrollment
30
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
30
Population
ALL · 60 Years to 80 Years
Duration
2020-06-01 to 2022-03-01
Intervention
Human umbilical cord mesenchymal stem cells（HUC-MSCs）; Placebo
Comparator
Control Group
Outcomes measured
Safety of HUC-MSCs infusion — Within one month post infusion; Difference in rate of decline of Frailty — Baseline, month 1, 3 month and 6 months post infusion; Difference in subject quality of life assessments — Baseline, month 1, month 3 and month 6 post infusion; Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts — Baseline, month 1,…; Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts — Baseline, month 1, month…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Stem cells · 100%Title contains controlled term: stem cell. Source terminology contains: stem cell. Title supplies longevity context: aging, frailty. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

stem cells
Open primary sourceExport JSON